Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...

GLP-1 receptor agonist use in the perioperative period should be based on shared decision-making of patient and care teams.

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...

Smoothie King just launched its GLP-1 Support Menu with five specific smoothie blends to help support the journey of individuals using GLP-1 weight loss medications like Ozempic and Wegovy – and ...

The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, ...

A new study reveals patients may continue to take their GLP-1 receptor agonists before undergoing elective surgery or ...